Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 140 No. 4344 (2010)

Anti-cytokine vaccination in autoimmune diseases

  • L Delavallée
  • E Duvallet
  • L Semerano
  • E Assier
  • MC Boissier
DOI
https://doi.org/10.4414/smw.2010.13108
Cite this as:
Swiss Med Wkly. 2010;140:w13108
Published
25.10.2010

Summary

The concept of therapeutic vaccination represents a novel strategy of active immunotherapy that can be applied to autoimmune disease. The principle is to design molecules which can trigger an immune response, targeting a cytokine that is pathogenic and over-expressed in a given disease. The mostly available vaccines are an application of vaccination using either the self-protein coupled to a carrier (type I A), or a modified form of the protein engineered to include neo-epitopes (type I B). These approaches have been developed in models of several autoimmune diseases, mainly in TNFα-dependent diseases such as rheumatoid arthritis and Crohn’s disease, but also in systemic lupus erythematosus, multiple sclerosis and myasthenia gravis. Clinical trials are in progress in rheumatoid arthritis, Crohn’s disease and diabetes. The benefit/risk ratio of anti-cytokine vaccination is currently under study to further develop the vaccination strategies.

References

  1. Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol. 2009;21(6):596–605.
  2. Delavallee L, Assier E, Denys A, et al. Vaccination with cytokines in autoimmune diseases. Ann Med. 2008;40(5):343–51.
  3. Oppenheim JJ, Feldmann M. Introduction to the role of cytokines in innate host defense and adaptative immunity. Cytokine References volume 1: Ligands. Oppenheim JJ, Feldmann M (Eds). Academic Press, London, UK, 3–20 (2000).
  4. Krause I, Valesini G, Scrivo R, et al. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003;115(5):390–7.
  5. Bruns A, Nicaise-Roland P, Hayem G, et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine. 2009;76(3):248–53.
  6. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol. 2004;14(1):11–20.
  7. Watanabe M, Uchida K, Nakagaki K, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007;581(10):2017–21.
  8. Rosenau BJ, Schur PH. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2009;36(4):753–6.
  9. Graudal NA, Svenson M, Tarp U, et al. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis. 2002;61(7):598–602.
  10. Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA. 2007;104(8):2837–42.
  11. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821–7.
  12. Delavallee L, Assier E, Semerano L, et al. Emerging applications of anticytokine vaccines. Expert Rev Vaccines. 2008;7(10):1507–17.
  13. Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol. 1999;17(7):666–9.
  14. Tan GH, Wang CC, Huang FY, et al. Active immunotherapy of allergic asthma with a recombinant human interleukin-5 protein as vaccine in a murine model. Chin Med J. (Engl). 2007;120(17):1517–22.
  15. Rohn TA, Jennings GT, Hernandez M, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36(11):2857–67.
  16. Delavallee L, Semerano L, Assier E, et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther. 2009;11(6):R195.
  17. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol. 2006;36(11):2868–74.
  18. Tighe H, Corr M, Roman M, et al. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today. 1998;19(2):89–97.
  19. Shen Y, Chen J, Zhang X, et al. Human TNF-alpha gene vaccination prevents collagen-induced arthritis in mice. Int Immunopharmacol. 2007;7(9):1140–9.
  20. Youssef S, Wildbaum G, Maor G, et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol. 1998;161(8):3870–9.
  21. He X, Tsang TC, Zhang T, et al. Antigen epitope-expressing cytokines for DNA immunization. Vaccine. 2005;23(16):1966–72.
  22. Dieude P. Rheumatic diseases: environment and genetics. Joint Bone Spine. 2009;76(6):602–7.
  23. Bloquel C, Denys A, Boissier MC, et al. Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice. J Gene Med. 2007.
  24. Khoury M, Escriou V, Courties G, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008;58(8):2356–67.
  25. Bizzini B, Achour A. “Kinoids”: the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol (Noisy-le-grand). 1995;41(3):351–6.
  26. Le Buanec H, Delavallee L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA. 2006;103(51):19442–7.
  27. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J. 1991;10(13):4025–31.
  28. Hayward MD, Jones BK, Saparov A, et al. An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol. 2007;7:13.
  29. Delavallee L, Le Buanec H, Bessis N, et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis. 2008;67(9):1332–8.
  30. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest. 2001;108(3):415–23.
  31. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol. 2007;178(11):7450–7.
  32. Wildbaum G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Immunol. 2000;165(10):5860–6.
  33. van de Loo AA, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis. 1990;49(4):238–45.
  34. Spohn G, Keller I, Beck M, et al. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol. 2008;38(3):877–87.
  35. Bertin-Maghit SM, Capini CJ, Bessis N, et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine. 2005;23(33):4228–35.
  36. Boissier MC, Assier E, Biton J, et al. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine. 2009;76(1):10–4.
  37. Galle P, Jensen L, Andersson C, et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int Immunopharmacol. 2007;7(13):1704–13.
  38. Onodera S, Ohshima S, Tohyama H, et al. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum. 2007;56(2):521–30.
  39. Goldberg R, Wildbaum G, Zohar Y, et al. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004;173(2):1171–8.
  40. Barnes DA, Tse J, Kaufhold M, et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest. 1998;101(12):2910–9.
  41. Youssef S, Maor G, Wildbaum G, et al. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest. 2000;106(3):361–71.
  42. Goldberg R, Zohar Y, Wildbaum G, et al. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004;173(10):6465–71.
  43. Wildbaum G, Karin, N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther. 1999;6(6):1128–38.
  44. Karpus WJ, Lukacs NW, McRae BL, et al. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 1995;155(10):5003–10.
  45. Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J Autoimmun. 1999;13(1):21–9.
  46. Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009;2009(979258).
  47. Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA. 2009;106(13):5294–9.
  48. Bossu, P, Neumann, D, Del Giudice E, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA. 2003;100(24):14181–6.
  49. Hauer AD, Uyttenhove C, de Vos P, et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112(7):1054–62.
  50. Sonderegger I, Rohn TA, Kurrer MO, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol. 2006;36(11):2849–56.
  51. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517–26.
  52. Uyttenhove C, Arendse B, Stroobant V, et al. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol. 2004;34(12):3572–81.